Pharma Focus Asia

Clearmind Medicine Secures Exclusive Long-Term Licensing Agreement with Leading Israeli Research Center

Friday, February 02, 2024

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY), a biotech company specializing in the discovery and development of novel psychedelic-derived therapeutics for under-treated health issues, has recently inked an exclusive long-term license agreement with BIRAD, a research and development company affiliated with Bar-Ilan University. This agreement grants Clearmind exclusive rights to a joint patent for an innovative cocaine treatment.

Dr. Adi Zuloff-Shani, CEO of Clearmind, emphasized the strategic decision to secure long-term exclusive rights to the technology following successful pre-clinical trials of MEAI, a novel psychedelic molecule developed by Clearmind. These trials, conducted in collaboration with Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University, demonstrated MEAI's effectiveness in reducing cocaine craving and addiction.

The pre-clinical trials utilized the self-administration paradigm, a gold-standard model for examining drug addiction based on operant conditioning. Animals treated with MEAI, particularly at a dose of 5 mg/kg, showed promising results in reducing the time spent in the compartment associated with cocaine. Furthermore, MEAI was found to abolish cocaine-induced conditioned place-preference, eliminate heightened craving, and demonstrate a lack of addictive properties.

In a subsequent trial involving cocaine self-administration, a sub-group of animals responded dramatically to MEAI treatment during the extinction phase, significantly decreasing craving compared to the non-treated control group. This sub-group, representing 60% of animals, exhibited a high response rate, aligning with previous research identifying a similar sub-population in the conditioned place-preference paradigm.

Dr. Zuloff-Shani expressed confidence in MEAI's potential to revolutionize cocaine addiction treatment, offering hope to millions globally. Clearmind aims to provide innovative solutions for addiction using psychedelic compounds, and this exclusive license agreement marks a significant step towards achieving that goal.



magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024